Stockholm-based pharmaceutical company Karo Bio AB has signed a deal with Pfizer Inc. for research collaboration that could see the Swedish company receive 217 million kroner (€24.2m) in upfront and milestone payments as well as in royalties from product sales, it was announced on 24 December.
Under the terms of the agreement, Pfizer will provide full funding for research costs and maintain exclusive rights to market any products that result from the collaboration.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.